Banco Bilbao Vizcaya Argentaria S.A. Has $19.43 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Banco Bilbao Vizcaya Argentaria S.A. lowered its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 74,693 shares of the medical research company's stock after selling 5,718 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Amgen were worth $19,434,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of AMGN. Burling Wealth Partners LLC acquired a new stake in Amgen in the fourth quarter worth approximately $242,000. Syon Capital LLC grew its holdings in Amgen by 2.8% during the fourth quarter. Syon Capital LLC now owns 6,783 shares of the medical research company's stock worth $1,768,000 after acquiring an additional 182 shares during the period. Coppell Advisory Solutions LLC lifted its holdings in Amgen by 10.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 5,923 shares of the medical research company's stock valued at $1,536,000 after acquiring an additional 537 shares during the last quarter. CSM Advisors LLC grew its stake in shares of Amgen by 35.7% in the 4th quarter. CSM Advisors LLC now owns 13,092 shares of the medical research company's stock worth $3,411,000 after purchasing an additional 3,444 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. raised its holdings in shares of Amgen by 12.9% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 36,971 shares of the medical research company's stock worth $9,636,000 after purchasing an additional 4,232 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Piper Sandler raised their target price on shares of Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Morgan Stanley boosted their target price on Amgen from $328.00 to $330.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 9th. UBS Group upped their price objective on shares of Amgen from $315.00 to $319.00 and gave the company a "neutral" rating in a research note on Monday, April 14th. Cantor Fitzgerald assumed coverage on shares of Amgen in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price objective on the stock. Finally, Johnson Rice set a $294.00 price target on Amgen in a research report on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Amgen presently has an average rating of "Hold" and a consensus price target of $310.57.

Amgen Price Performance

NASDAQ AMGN traded up $4.60 during trading hours on Tuesday, reaching $287.69. 837,311 shares of the company's stock were exchanged, compared to its average volume of 3,136,012. The firm has a fifty day moving average of $301.29 and a 200-day moving average of $292.11. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The stock has a market cap of $154.67 billion, a PE ratio of 38.10, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio is presently 126.09%.

Insider Transactions at Amgen

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 69,341 shares of company stock worth $20,644,335. Corporate insiders own 0.69% of the company's stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.